Literature DB >> 15251612

Growth hormone, skeletal growth factors and osteoporosis.

E Canalis1.   

Abstract

Bone remodeling is regulated by systemic hormones and growth factors acting in concert to maintain normal bone mass. Growth hormone has important effects on bone metabolism and acts by stimulating the production of insulin-like growth factor (IGF) I in the liver. Conditions of growth hormone deficiency have decreased bone mass that could be modified by growth hormone administration. Skeletal cells synthesize a variety of growth factors with diverse properties and levels of regulation. IGF I and II seem to play a major role in the local regulation of bone remodeling, and other growth factors have important mitogenic properties. Skeletal growth factors may be regulated at the level of synthesis, activation, receptor binding or binding proteins. Growth factors such as IGF I could be considered for the systemic treatment of various bone disorders, or drugs could be developed to modify the synthesis or activity of the locally produced factors. Additional research should result in the development of novel approaches to the treatment of osteoporosis.

Entities:  

Year:  1995        PMID: 15251612     DOI: 10.4158/EP.1.1.39

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  3 in total

1.  Conditional deletion of insulin-like growth factor-I in collagen type 1alpha2-expressing cells results in postnatal lethality and a dramatic reduction in bone accretion.

Authors:  Kristen E Govoni; Jon E Wergedal; Lore Florin; Peter Angel; David J Baylink; Subburaman Mohan
Journal:  Endocrinology       Date:  2007-08-23       Impact factor: 4.736

2.  Insulin-like growth factors and their role in osteoporosis.

Authors:  E Canalis; D Agnusdei
Journal:  Calcif Tissue Int       Date:  1996-03       Impact factor: 4.333

3.  Impact of concurrent diabetes on periodontal health in patients with acromegaly.

Authors:  Akanksha Jain; Shipra Gupta; Anil Bhansali; Mili Gupta; Ashish Jain; Nandini Bhaskar; Rose Kanwaljeet Kaur
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.